MX2023006704A - Dsg2 compositions and methods for the treatment of covid-19. - Google Patents

Dsg2 compositions and methods for the treatment of covid-19.

Info

Publication number
MX2023006704A
MX2023006704A MX2023006704A MX2023006704A MX2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A MX 2023006704 A MX2023006704 A MX 2023006704A
Authority
MX
Mexico
Prior art keywords
methods
compositions
covid
treatment
dsg2
Prior art date
Application number
MX2023006704A
Other languages
Spanish (es)
Inventor
Shi Yin Foo
Ryan Edward Tyler
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of MX2023006704A publication Critical patent/MX2023006704A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The disclosure generally relates to compositions and methods of treating COVID-19 by administering compositions disclosed herein. The methods also include the treatment of post-COVID-19 syndrome and cardiomyopathies using compositions described in the present disclosure.
MX2023006704A 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19. MX2023006704A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US202163274715P 2021-11-02 2021-11-02
PCT/US2021/063433 WO2022132854A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Publications (1)

Publication Number Publication Date
MX2023006704A true MX2023006704A (en) 2023-06-20

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006704A MX2023006704A (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19.

Country Status (9)

Country Link
EP (1) EP4263588A1 (en)
JP (1) JP2024500250A (en)
KR (1) KR20230120141A (en)
AU (1) AU2021400845A1 (en)
CA (1) CA3202364A1 (en)
IL (1) IL303444A (en)
MX (1) MX2023006704A (en)
TW (1) TW202237634A (en)
WO (1) WO2022132854A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312219A (en) * 2021-11-02 2024-06-01 Arvada Therapeutics Inc Dsg2 compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (en) 1998-09-15 2002-08-27 한미약품(주) Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same
DE10057397A1 (en) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Device for oil level measurement in internal combustion engine, particularly in road vehicle, has housing at base of which vertically extending, elongated damping container is fitted, which is connectable to oil feed
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments

Also Published As

Publication number Publication date
TW202237634A (en) 2022-10-01
WO2022132854A1 (en) 2022-06-23
CA3202364A1 (en) 2022-06-23
EP4263588A1 (en) 2023-10-25
KR20230120141A (en) 2023-08-16
IL303444A (en) 2023-08-01
JP2024500250A (en) 2024-01-05
AU2021400845A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
MX2022001607A (en) Compositions and methods of treating psoriasis and atopic dermatitis using prevotella histicola.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2019013279A (en) Methods of treating doose syndrome using fenfluramine.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2023007212A (en) Epinephrine spray formulations.
MX2021012391A (en) Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes.
EA202193111A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
MX2023004156A (en) Combination therapy for treating cancer.
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
MX2021011230A (en) Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases.
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
MX2023006704A (en) Dsg2 compositions and methods for the treatment of covid-19.
EA202193276A1 (en) METHODS FOR THE TREATMENT OF CHOLANGIOCARCINOMA
MX2022005250A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies.
MX2021011986A (en) Methods of treating neuropathic pain.
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
MX2022012001A (en) Preventative treatment of migraine.
MX2023004881A (en) Pde9 inhibitors for treating cardiac failure.
MX2022012404A (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases.
MX2023005031A (en) Degradant compound in a medicament.
MX2022004945A (en) TREATMENT OF EPILEPTIC CONDITIONS WITH GABA<sub>A</sub> RECEPTOR MODULATORS.
MX2022004785A (en) Methods and compositions for treatment of rett syndrome.
MX2023001723A (en) Cyclic chemerin-9 derivatives.
WO2021011875A8 (en) Compositions and methods for treating skin conditions
MX2022008632A (en) Ccr5 binding agent for treatment of ccr5 positive metastatic cancer.